EUCTR2004-002834-20-AT进行中（未招募）不适用
Behandlung des fortgeschrittenen hepatozellulären Karzinoms mit dem mTOR-Inhibitor Rapamycin (HCC-Rap-001)Treatment of advanced hepatocellular carcinoma with the mTOR-inhibitor rapamycin (HCC-Rap-001) - treatment of HCC with rapamycin
niversitätsklinik für Innere Medizin IV, Klinische Abteilung Gastroenterologie und Hepatologie0 个研究点目标入组 30 人开始时间: 2008年1月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •histologically verified hepatocellular carcinoma, not suitable for surgery, liver transplantation, embolization, kryotherpay, ethanol instillation, radio frequency ablation.
- •No previous therapy
- •liver cirrhosis Child A or B
- •Thrombocytes > 30.0 x 10E9 / L
- •Leukozyten > 1.0 x 10E9 / L
- •Age 19 - 85
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •WHO performance status > 2
- •estimated life expectancy < 3 months
- •acute infection
- •HIV positivity
- •pregnancy, breast feeding, lack of contraception
- •other malignant disease within past 5 years
研究者
相似试验
尚未招募
不适用
Choices of therapeutic strategies for hepatocellular carcinoma (HCC)C22.0Liver cell carcinomaDRKS00025099Chirurgische Klinik, Universitätsmedizin Mannheim200
尚未招募
Unknown
Systemic therapy for Unresectable Hepatocellular Carcinoma: Therapeutic Effectiveness by Treatment Modality and Optimal Drug Use Ordernresectable hepatocellular carcinomaJPRN-UMIN000051797Japanese Red Cross Society Himeji Hospital5,000
进行中（未招募）
不适用
Treatment of advanced hepatocellular carcinoma (HCC) with portal vein thrombosis by hepatic intra-arterial injection of microspheres loaded with Yttrium-90 (Thera-Sphere) - RAD-09advanced hepatocellular carcinoma (HCC) with portal vein thrombosisMedDRA version: 9.1Level: LLTClassification code 10024662MedDRA version: 9.1Level: PTClassification code 10019713EUCTR2009-016475-29-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
尚未招募
不适用
Resection of initially unresectable hepatocellular carcinoma with atezolizumab plus bevacizumab Additional study: Identification of biomarkers for predicting therapeutic effects and adverse eventsHepatocellular CarcinomaJPRN-UMIN000046634ational Center for Global Health and Medicine50
招募中
不适用
RACB StudyHepatocellular CarcinomaJPRN-jRCTs051210148Hatano Etsuro50